Diagnostic accuracy and sensitivity values for anti-tuberculosis drugs (graded mutations identified by Miotto et al. [13] were used within the new classification of the World Health Organization [12]).
| Drug class | Drug (genomic region targeted) | Clinical interpretation of graded mutations as marker of resistance (high+moderate+minimal) | |
| Diagnostic accuracy % | Sensitivity % | ||
| First-line | Rifampicin (rpoB) | 94 | 90.5 |
| Isoniazid (katG, inhA-mabA, furA, mshA) | 80.7 | 78.3 | |
| Second-line (group A) | Ofloxacin/levofloxacin (gyrA, gyrB) Moxifloxacin (gyrA, gyrB) | 90.9 94 | 81.7 89.2 |
| Second-line (group B) | Amikacin (rrs) | 91.8 | 78.8 |
| Capreomycin (rrs, tlyA) | 92 | 71.3 | |
| Kanamycin (rrs, eis, whiB7) | 87.7 | 68.3 | |
| Streptomycin (rpsL, rrs, gidB, tap, whiB7) | 76.4 | 61.3 | |
| Second-line (group C) | Ethionamide/prothionamide (inhA-mabA, ethA, mshA) | 67.5 | 48.5 |
| Second-line (group D) | Pyrazinamide (pncA) | 76.8 | 53.1 |